PE20060172A1 - ACIDOS HETEROCICLILACETICOS COMO INHIBIDORES DE TAFIa - Google Patents
ACIDOS HETEROCICLILACETICOS COMO INHIBIDORES DE TAFIaInfo
- Publication number
- PE20060172A1 PE20060172A1 PE2005000382A PE2005000382A PE20060172A1 PE 20060172 A1 PE20060172 A1 PE 20060172A1 PE 2005000382 A PE2005000382 A PE 2005000382A PE 2005000382 A PE2005000382 A PE 2005000382A PE 20060172 A1 PE20060172 A1 PE 20060172A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- cyclohexil
- aminopyridin
- imidazol
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 2
- SFAMKDPMPDEXGH-UHFFFAOYSA-N 2-hydroxyethyl propanoate Chemical compound CCC(=O)OCCO SFAMKDPMPDEXGH-UHFFFAOYSA-N 0.000 abstract 1
- -1 AMINO Chemical group 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000020764 fibrinolysis Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
- 201000005665 thrombophilia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004020186A DE102004020186A1 (de) | 2004-04-22 | 2004-04-22 | Heterocyclylessigsäuren als Inhibitoren von TAFla |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060172A1 true PE20060172A1 (es) | 2006-03-31 |
Family
ID=34964308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000382A PE20060172A1 (es) | 2004-04-22 | 2005-04-06 | ACIDOS HETEROCICLILACETICOS COMO INHIBIDORES DE TAFIa |
Country Status (34)
| Country | Link |
|---|---|
| EP (2) | EP1864979B1 (https=) |
| JP (1) | JP4939401B2 (https=) |
| KR (1) | KR101162047B1 (https=) |
| CN (1) | CN100572376C (https=) |
| AR (1) | AR053302A1 (https=) |
| AT (2) | ATE386737T1 (https=) |
| AU (1) | AU2005238144B2 (https=) |
| BR (1) | BRPI0510159A (https=) |
| CA (1) | CA2563401C (https=) |
| CR (1) | CR8650A (https=) |
| CY (1) | CY1108087T1 (https=) |
| DE (2) | DE102004020186A1 (https=) |
| DK (1) | DK1740569T3 (https=) |
| EC (1) | ECSP066941A (https=) |
| ES (1) | ES2299026T3 (https=) |
| HR (1) | HRP20080099T3 (https=) |
| IL (1) | IL178672A (https=) |
| MA (1) | MA28543B1 (https=) |
| MY (1) | MY140903A (https=) |
| NI (1) | NI200600217A (https=) |
| NO (1) | NO20065320L (https=) |
| NZ (1) | NZ550757A (https=) |
| PE (1) | PE20060172A1 (https=) |
| PL (1) | PL1740569T3 (https=) |
| PT (1) | PT1740569E (https=) |
| RS (1) | RS50553B (https=) |
| RU (1) | RU2375356C2 (https=) |
| SI (1) | SI1740569T1 (https=) |
| TN (1) | TNSN06341A1 (https=) |
| TW (1) | TWI359016B (https=) |
| UA (1) | UA87306C2 (https=) |
| UY (1) | UY28868A1 (https=) |
| WO (1) | WO2005105781A1 (https=) |
| ZA (1) | ZA200607668B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150514T1 (hr) | 2006-12-06 | 2015-09-11 | Sanofi | DERIVATI SULFAMIDA KAO INHIBITORI TAFIa |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| MX2009008777A (es) * | 2007-02-13 | 2009-08-25 | Schering Corp | Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
| AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| WO2009103432A2 (en) * | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
| SI2300462T1 (sl) | 2008-06-06 | 2014-09-30 | Sanofi | Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa |
| NZ592764A (en) | 2008-10-29 | 2012-08-31 | Taisho Pharmaceutical Co Ltd | Compound having tafia inhibitory activity |
| KR20120016651A (ko) * | 2009-05-15 | 2012-02-24 | 사노피 | Ｔａｆｉａ의 억제제로서 유용한 화합물의 제조방법 |
| FR2947266B1 (fr) * | 2009-06-26 | 2011-06-17 | Servier Lab | Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US8410127B2 (en) | 2009-10-01 | 2013-04-02 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| KR20130006620A (ko) * | 2010-03-18 | 2013-01-17 | 다이이찌 산쿄 가부시키가이샤 | 시클로프로판카르복실산 유도체 |
| DK2548871T3 (da) | 2010-03-18 | 2017-11-06 | Daiichi Sankyo Co Ltd | Cycloalkylsubstitueret imidazolderivat |
| MX2013004193A (es) * | 2010-11-11 | 2013-06-05 | Sanofi Sa | Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico. |
| EP2782576B1 (en) | 2011-11-25 | 2016-05-18 | Sanofi | Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid |
| EP2782574B1 (de) | 2011-11-25 | 2016-03-30 | Sanofi | Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester |
| EP2782575B1 (en) | 2011-11-25 | 2016-04-20 | Sanofi | Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid |
| EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
| CA2914533A1 (en) | 2013-06-10 | 2014-12-18 | Sanofi | Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals |
| EP3437641A4 (en) | 2016-03-29 | 2019-11-20 | Daiichi Sankyo Company, Limited | THERAPEUTIC AGENT AGAINST INFLAMMATORY DARMER DISEASE |
| AU2017305392A1 (en) | 2016-08-03 | 2019-02-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0104657A3 (en) * | 1998-12-24 | 2002-07-29 | Astellas Pharma Inc Chuo Ku | Imidazole compounds and pharmaceutical compositions containing them |
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| WO2003061653A1 (en) | 2002-01-22 | 2003-07-31 | Pfizer Limited | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
-
2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/de not_active Withdrawn
-
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/es not_active Application Discontinuation
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/sr unknown
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/ja not_active Expired - Fee Related
- 2005-04-07 CA CA2563401A patent/CA2563401C/en not_active Expired - Fee Related
- 2005-04-07 PT PT05731221T patent/PT1740569E/pt unknown
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/ko not_active Expired - Fee Related
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/zh not_active Expired - Fee Related
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/ru not_active IP Right Cessation
- 2005-04-07 ES ES05731221T patent/ES2299026T3/es not_active Expired - Lifetime
- 2005-04-07 EP EP07017340A patent/EP1864979B1/de not_active Expired - Lifetime
- 2005-04-07 AT AT05731221T patent/ATE386737T1/de active
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/pt not_active Application Discontinuation
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/de not_active Expired - Lifetime
- 2005-04-07 AT AT07017340T patent/ATE523505T1/de active
- 2005-04-07 HR HR20080099T patent/HRP20080099T3/xx unknown
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/de not_active Ceased
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 PL PL05731221T patent/PL1740569T3/pl unknown
- 2005-04-07 SI SI200530185T patent/SI1740569T1/sl unknown
- 2005-04-07 EP EP05731221A patent/EP1740569B1/de not_active Expired - Lifetime
- 2005-04-07 DK DK05731221T patent/DK1740569T3/da active
- 2005-04-20 AR ARP050101556A patent/AR053302A1/es not_active Application Discontinuation
- 2005-04-20 TW TW094112493A patent/TWI359016B/zh not_active IP Right Cessation
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-22 UY UY28868A patent/UY28868A1/es unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/ru unknown
-
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/es unknown
- 2006-09-22 CR CR8650A patent/CR8650A/es unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/fr unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/es unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/no not_active Application Discontinuation
-
2008
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060172A1 (es) | ACIDOS HETEROCICLILACETICOS COMO INHIBIDORES DE TAFIa | |
| PE20120993A1 (es) | Derivados bifenilicos como antivirales | |
| PE20070602A1 (es) | Compuestos de carboxiamina como moduladores de histona desacetilasa | |
| AR051778A2 (es) | Derivados del acido dimetilaminocrotonico y procesos para supreparacion | |
| BRPI0306559B8 (pt) | composição farmacêutica para aplicação oral para mesilato de etilésteres de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2-il-amino]-propiônico e seu processo de preparação | |
| PE20030976A1 (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
| DE60026404D1 (de) | Verfahren zur Herstellung von Benzothiophen-Derivaten | |
| EP1187599A4 (en) | STABLE BENZIMIDAZOL COMPOSITIONS | |
| UA101328C2 (uk) | Похідні 6-триазолпіридинсульфанілбензотіазолу і -бензімідазолу, спосіб їх одержання (варіанти), застосування їх як лікарських засобів, фармацевтична композиціїя та застосування як інгібіторів met | |
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| CL2008003324A1 (es) | Formulacion farmaceutica liquida de liberacion inmediata que comprende una sal de adicion de acido de un compuesto derivado de azetidina sustituido y un diluyente o portador farmaceuticamente aceptable, util para el tratamiento o prevencion de trombosis. | |
| NZ592705A (en) | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication | |
| PE20050342A1 (es) | Tableta que contiene el ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico o sus sales | |
| PE20080843A1 (es) | Inhibidores de renina y metodo para su utilizacion | |
| PE20091309A1 (es) | Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa | |
| PE20090243A1 (es) | Compuestos de imidazol sustituido como inhibidores de renina | |
| CO6361934A2 (es) | Composicion farmaceutica solida | |
| WO2006028269A3 (en) | Thiazole derivatives having vap-1 ihibitory activity | |
| MXPA04009476A (es) | Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7. | |
| TR200301248A2 (tr) | Antibiyotik Aktiviteye Sahip Olan Farmasotik Kompozisyonlar. | |
| CY1113805T1 (el) | Μεσυλικο αιθυλαμιδιο του 5-(2,4-διυδροξυ-5-ισοπροπυλο-φαινυλο)-4-(4-μορφολιν-4-υλομεθυλοφαινυλ)-ισοξαζολο-3-καρβοξυλικου οξεος, ενυδρα αλατα και πολυμορφα της ενωσης αυτης και σκευασματα τα οποια περιεχουν αυτες τις μορφες | |
| KR920703628A (ko) | 티로트로핀-방출 호르몬(trh)의 프로드러그 유도체 | |
| PE20130179A1 (es) | Nuevos derivados terciarios de 8-hidroxiquinolina-7-carboxamida | |
| MX2025007492A (es) | Compuestos lipidicos y composiciones de nanoparticulas lipidicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |